Table 1

Patient-reported outcome measures

All reached patientsNo symptomatic improvementSymptomatic improvementP values
N50768408
Follow-up duration in days (median (IQR))757 (465–1139)755 (514–1146)764 (463–1129)0.708
Residual impairment (%)*190 (38.1)68 (100)119 (29.2)<0.001
Percentage of main symptom remedied (median (IQR))80 (60–90)60 (25–80)80 (65–90)<0.001
Main symptom remedied (n (%))†208 (68.6)28 (66.7)165 (68.2)0.988
Would undergo TAVI again (n (%))428 (89.9)56 (86.2)348 (90.6)0.375
  • Symptomatic improvement defined as decrease in NYHA class after 30 days post-TAVI.

  • *Residual impairment is defined as not returning to having no functional impairment, that is, NYHA 1, after TAVI procedure.

  • †Main symptom remedied was defined as a >50% improvement of the main symptom.

  • NYHA, New York Heart Association; TAVI, transcatheter aortic valve implantation.